Oncology & Cancer

Nexavar approval expanded for common thyroid cancer

(HealthDay)—U.S. Food and Drug Administration approval for the anti-cancer drug Nexavar (sorafenib) has been expanded to include late-stage differentiated thyroid cancer, the most common type of thyroid cancer.

Oncology & Cancer

Patient decision aid beneficial in papillary thyroid cancer

(HealthDay) -- Patients with early-stage papillary thyroid cancer (PTC) may benefit from the use of a patient-directed computerized decision aid (DA) to provide medical knowledge and resolve decisional conflicts regarding ...

page 2 from 2